Alemtuzumab in the treatment of multiple sclerosis
Óscar Fernandez Institute of Clinical Neuroscience, Neurology Department, Hospital Regional Universitario Carlos Haya, FIMABIS, Malaga, Spain Abstract: Alemtuzumab (formerly known as Campath-1H) has recently been approved by the European Medicines Agency for highly-active, relapsing-rem...
Guardado en:
Autor principal: | Fernandez Ó |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/74a7d160c74b48a585fc912165f59d34 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Emerging therapies for treatment of multiple sclerosis
por: John R Corboy, et al.
Publicado: (2010) -
Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Slobodan M Jankovic
Publicado: (2010) -
The effect of smoking on the symptoms and progression of multiple sclerosis: a review
por: Afsaneh Shirani, et al.
Publicado: (2010) -
Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients [Corrigendum]
por: Taheri M, et al.
Publicado: (2019) -
Vascular involvement in systemic sclerosis (scleroderma)
por: Pattanaik D, et al.
Publicado: (2011)